Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 16/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.57 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381148 | 1.00 | MCHR1 (0.57) | MCHR1CHRM1HTR2ACYP2D6CXCR3 | |
| SCHEMBL5157670 | 1.00 | MCHR1 (0.57) | MCHR1CHRM1HTR2ACYP2D6CXCR3 | |
| SCHEMBL2324207 | 0.88 | MCHR1 (0.58) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL4476797 | 0.88 | MCHR1 (0.60) | MCHR1CHRM1HTR2ACYP2D6CXCR3 | |
| SCHEMBL4472200 | 0.86 | MCHR1 (0.61) | MCHR1CHRM1HTR2ACYP2D6CXCR3 | |
| SCHEMBL6379658 | 0.85 | MCHR1 (0.56) | MCHR1CHRM1HTR2ACYP2D6CXCR3 | |
| SCHEMBL4477515 | 0.85 | MCHR1 (0.60) | MCHR1CHRM1HTR2ACYP2D6CXCR3 | |
| SCHEMBL5155466 | 0.85 | MCHR1 (0.55) | MCHR1CHRM1HTR2ACYP2D6CXCR3 | |
| SCHEMBL5151360 | 0.82 | MCHR1 (0.56) | MCHR1CHRM1HTR2ACYP2D6CXCR3 | |
| SCHEMBL4481226 | 0.81 | MCHR1 (0.59) | MCHR1CHRM1HTR2ACYP2D6CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740572-A1 | NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005103031-A1 | NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239826-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239826-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MCHR2, GPR119 | MCHR1 1/4885CHRM1 47/4885HTR2A 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.